Cantor Fitzgerald analyst Kristen Kluska downgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Overweight to Neutral with a price target of $36.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE